Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Progesterone Receptor Liquid Biopsy Test

Biocept has announced the commercial availability of its liquid biopsy test for progesterone receptor (PR), which can be used for the detection and monitoring of a key biomarker in the blood of patients with breast cancer. The company noted that the ability to detect PR expression in circulating tumor cells complements its existing ER and HER2 assays for biomarker analysis in breast cancer. Biocept's Target Selector PR expression test is performed on circulating tumor cells using fluorescently labeled antibodies. The company's liquid biopsy tests are performed in its CLIA-certified, CAP-accredited laboratory in San Diego.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.